Age-Related Neurodegeneration and Memory Loss in Down Syndrome
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Down syndrome (DS) is a condition where a complete or segmental chromosome 21 trisomy causes variable intellectual disability, and progressive memory loss and neurodegeneration with age. Many research groups have examined development of the brain in DS individuals, but studies on age-related changes should also be considered, with the increased lifespan observed in DS. DS leads to pathological hallmarks of Alzheimer's disease (AD) by 40 or 50 years of age. Progressive age-related memory deficits occurring in both AD and in DS have been connected to degeneration of several neuronal populations, but mechanisms are not fully elucidated. Inflammation and oxidative stress are early events in DS pathology, and focusing on these pathways may lead to development of successful intervention strategies for AD associated with DS. Here we discuss recent findings and potential treatment avenues regarding development of AD neuropathology and memory loss in DS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oxidative Damage Is the Earliest Event in Alzheimer Disease
Nunomura, A., Perry, G., Aliev, G., Hirai, K., Takeda, A., Balraj, E. K., Jones, P. K., Ghanbari, H., Wataya, T., Shimohama, S., et al. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.8.759 · Cited by 1,885 · cited 1×
“A marker of RNA oxidative damage, 8-hydroxyguanosine (8-OHG), is elevated in neurons of the hippocampus and cortex early in the progression of AD and precedes much of the pathology in these regions, suggesting that oxidative stress may be the earliest event in AD-related disease processes [124].”
BackgroundA mouse model for Down syndrome exhibits learning and behaviour deficits
Reeves, R. H., Irving, N. G., Moran, T. H., Wohn, A., Kitt, C., Sisodia, S. S., Schmidt, C., Bronson, R. T., & Davisson, M. T. (1995) · Nature Genetics · doi:10.1038/ng1095-177 · Cited by 913 · cited 1×
“Ts65Dn mice show consistent learning and memory deficits on spatial reference and working memory tasks [56, 61–67].”
BackgroundDe Felice, F. G., Velasco, P. T., Lambert, M. P., Viola, K., Fernandez, S. J., Ferreira, S. T., & Klein, W. L. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m607483200 · Cited by 882
The pathological process underlying Alzheimer’s disease in individuals under thirty
Braak, H., & Del Tredici, K. (2011) · Acta Neuropathologica · doi:10.1007/s00401-010-0789-4 · Cited by 812 · cited 1×
“Progressive age-related memory deficits occurring in both AD and in DS have been connected to degeneration of several neuronal populations, but mechanisms are not fully elucidated.”
BackgroundChromosome 21 and Down syndrome: from genomics to pathophysiology
Antonarakis, S. E., Lyle, R., Dermitzakis, E. T., Reymond, A., & Deutsch, S. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1448 · Cited by 703 · cited 2×
“More importantly, these mice exhibit normal lifespans, allowing for the analysis of progressive neurodegenerative alterations.”
BackgroundWoolley, J. D., Khan, B. K., Murthy, N. K., Miller, B. L., & Rankin, K. P. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10m06382oli · Cited by 549 · cited 1×
“The most common cause of dementia is Alzheimer’s disease (AD), with rates of prevalence increasing steadily from 60 years of age to reach almost 40% by the age of 85 [1].”
BackgroundBerchtold, N. C., Chinn, G., Chou, M., Kesslak, J. P., & Cotman, C. W. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.03.026 · Cited by 471
Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome
Holtzman, D. M., Santucci, D., Kilbridge, J., Chua-Couzens, J., Fontana, D. J., Daniels, S. E., Johnson, R. M., Chen, K., Sun, Y., Carlson, E., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.23.13333 · Cited by 448
The neuropathology of aminergic nuclei in Alzheimer's disease
Zweig, R. M., Ross, C. A., Hedreen, J. C., Steele, C., Cardillo, J. E., Whitehouse, P. J., Folstein, M. F., & Price, D. L. (1988) · Annals of Neurology · doi:10.1002/ana.410240210 · Cited by 446
Grudzien, A., Shaw, P., Weintraub, S., Bigio, E., Mash, D. C., & Mesulam, M. M. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.02.007 · Cited by 396 · cited 1×
“Cortical neuronal loss is preceded by degeneration of certain subcortical neuronal populations, including basal forebrain cholinergic neurons (BFCNs) [3] and noradrenergic neurons of the locus coeruleus (LC-NE) [4, 5].”
BackgroundInflammation and neurodegenerative diseases
Griffin, W. S. T. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.2.470s · Cited by 351 · cited 1×
“As in AD, individuals with DSD consistently exhibit chronic inflammation in limbic system areas of the brain, with increases in microglial and astrocytic activation coupled with IL-1β and TNF-α cytokine release [91–93].”
BackgroundCooper, J. D., Salehi, A., Delcroix, J.-D., Howe, C. L., Belichenko, P. V., Chua-Couzens, J., Kilbridge, J. F., Carlson, E. J., Epstein, C. J., & Mobley, W. C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.181219298 · Cited by 336 · cited 2×
“Ts65Dn mice also show increased inflammatory morphology with aging [22, 46] (see also Figure 2) synaptic dysfunction [47, 48], and a failure of neurotrophic signaling, particularly involving the retrograde transport of nerve growth factor (NGF) to the basal forebrain [42, 46, 49, 50], and downregulation of brain-deriv…”
BackgroundExecutive function in adolescents with Down Syndrome
Lanfranchi, S., Jerman, O., Dal Pont, E., Alberti, A., & Vianello, R. (2010) · Journal of Intellectual Disability Research · doi:10.1111/j.1365-2788.2010.01262.x · Cited by 308 · cited 1×
“Studies assessing the effects of age on cognition in DS demonstrate a greater incidence of short-term memory impairment in DS individuals over 35 years of age, as well as increasing rates of dementia, aphasia, and agnosia [23] while detriments in executive function are evident already in adolescence [24].”
BackgroundHeneka, M. T., Ramanathan, M., Jacobs, A. H., Dumitrescu-Ozimek, L., Bilkei-Gorzo, A., Debeir, T., Sastre, M., Galldiks, N., Zimmer, A., Hoehn, M., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.4236-05.2006 · Cited by 305 · cited 2×
“NE terminal destruction also impeded cholinergic neurotransmission in AD models which otherwise show no cholinergic deficits [81].”
BackgroundResultRecent advances in our understanding of neurodegeneration
Jellinger, K. A. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0240-y · Cited by 274 · cited 1×
“BDNF and NGF have been associated with neuroprotection against oxidative stress in neurons [119, 120], suggesting that DSD patients may exhibit increased sensitivity to oxidative stress because of reduced expression of these neurotrophic factors.”
BackgroundGene expression profiling in the adult Down syndrome brain
Lockstone, H. E., Harris, L. W., Swatton, J. E., Wayland, M. T., Holland, A. J., & Bahn, S. (2007) · Genomics · doi:10.1016/j.ygeno.2007.08.005 · Cited by 240 · cited 1×
“While trisomy 21 constitutes the triplication of over 300 genes [30, 31], recent animal studies have sought to elucidate which genes may contribute to the observed neurodegenerative pathology.”
BackgroundMassaad, C. A., Washington, T. M., Pautler, R. G., & Klann, E. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902714106 · Cited by 223 · cited 9×
“SOD-1 overexpression alone also gave rise to ROS accumulation, but not to the extent observed in APP/SOD-1 overexpression mice, suggesting a comodulation of oxidative stress pathways by the APP and SOD-1 genetic overexpression [37].”
BackgroundInfluentialExercise improves cognition and hippocampal plasticity in APOE ɛ4 mice
Nichol, K., Deeny, S. P., Seif, J., Camaclang, K., & Cotman, C. W. (2009) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2009.02.006 · Cited by 213
Alzheimer disease and Down syndrome: factors in pathogenesis
Lott, I. T., & Head, E. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.08.005 · Cited by 212 · cited 1×
“Microglial activation typically arises in the entorhinal cortex before developing in the hippocampus and surrounding cortex as well as the basal forebrain [26, 27].”
BackgroundKoshimizu, H., Kiyosue, K., Hara, T., Hazama, S., Suzuki, S., Uegaki, K., Nagappan, G., Zaitsev, E., Hirokawa, T., Tatsu, Y., et al. (2009) · Molecular Brain · doi:10.1186/1756-6606-2-27 · Cited by 195
Excitatory-inhibitory relationship in the fascia dentata in the Ts65Dn mouse model of down syndrome.
Belichenko, P. V., Kleschevnikov, A. M., Masliah, E., Wu, C., Takimoto‐Kimura, R., Salehi, A., & Mobley, W. C. (2009) · Journal of Comparative Neurology · doi:10.1002/cne.21895 · Cited by 141 · cited 1×
“Ts65Dn mice also show increased inflammatory morphology with aging [22, 46] (see also Figure 2) synaptic dysfunction [47, 48], and a failure of neurotrophic signaling, particularly involving the retrograde transport of nerve growth factor (NGF) to the basal forebrain [42, 46, 49, 50], and downregulation of brain-deriv…”
BackgroundMechanisms of Disease: DNA repair defects and neurological disease
Subba Rao, K. (2007) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0448 · Cited by 121
Hyde, L. A., Frisone, D. F., & Crnic, L. S. (2001) · Behavioural Brain Research · doi:10.1016/s0166-4328(00)00313-2 · Cited by 108 · cited 1×
“Ts65Dn mice show consistent learning and memory deficits on spatial reference and working memory tasks [56, 61–67].”
BackgroundLiu, Y.-F., Chen, H.-I., Yu, L., Kuo, Y.-M., Wu, F.-S., Chuang, J.-I., Liao, P.-C., & Jen, C. J. (2008) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2008.02.005 · Cited by 98
Atomoxetine and Stroop Task Performance in Adult Attention-Deficit/Hyperactivity Disorder
Faraone, S. V., Biederman, J., Spencer, T., Michelson, D., Adler, L., Reimherr, F., & Seidman, L. (2005) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2005.15.664 · Cited by 89 · cited 1×
“Further, treatment with NE enhancing drugs, such as Atomoxetine (Strattera) [88, 135], has shown promising results in children with ADHD and in PD; it is possible that these pharmaceutical interventions may be beneficial for working memory deficits and early onset problems with executive function in persons with DSD a…”
Backgroundets-2 Promotes the Activation of a Mitochondrial Death Pathway in Down's Syndrome Neurons
Helguera, P., Pelsman, A., Pigino, G., Wolvetang, E., Head, E., & Busciglio, J. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.5107-04.2005 · Cited by 88 · cited 9×
“SOD-1 overexpression alone also gave rise to ROS accumulation, but not to the extent observed in APP/SOD-1 overexpression mice, suggesting a comodulation of oxidative stress pathways by the APP and SOD-1 genetic overexpression [37].”
BackgroundInfluentialSiarey, R. J., Kline‐Burgess, A., Cho, M., Balbo, A., Best, T. K., Harashima, C., Klann, E., & Galdzicki, Z. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03971.x · Cited by 86
Choi, J. H. K., Berger, J. D., Mazzella, M. J., Morales‐Corraliza, J., Cataldo, A. M., Nixon, R. A., Ginsberg, S. D., Levy, E., & Mathews, P. M. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06277.x · Cited by 83
Research works printed but not linked: 108
- 2010, Advances in Experimental Medicine and Biology, 685, 34, 10.1007/978-1-4419-6448-9_4 · DOI
- 10.1016/j.bbr.2010.11.058 · DOI · Paper page
- 10.1111/j.1440-1789.2006.00725.x · DOI · Paper page
- 10.1007/s00401-009-0521-4 · DOI
- 10.1371/journal.pone.0010659 · DOI · Paper page
- 10.1016/S1474-4422(10)70112-5 · DOI · Paper page
- 1996, Nature Medicine, 2, 93, 10.1038/nm0196-93 · DOI · Paper page
- 10.1001/archneurol.2011.104 · DOI · Paper page
- 10.1136/jnnp.2006.113514 · DOI · Paper page
- 10.1016/j.cbi.2009.11.018 · DOI
- 10.2174/156720507780362164 · DOI · Paper page
- 2009, Cochrane Database of Systematic Reviews
- 2009, Cochrane Database of Systematic Reviews
- 10.1002/ajmg.a.32581 · DOI
- 10.1002/gcc.20764 · DOI
- 1982, National Cancer Institute Monograph, 60, 241
- 10.3233/JAD-2010-101218 · DOI · Paper page
- 10.1002/gps.502 · DOI · Paper page
- 10.1002/gps.1077 · DOI · Paper page
- 10.1002/mrdd.1025 · DOI · Paper page
- 10.2353/ajpath.2008.071053 · DOI · Paper page
- 2000, American Journal of Pathology, 157, 277, 10.1016/S0002-9440(10)64538-5 · DOI · Paper page
- 10.1007/s00415-002-0799-9 · DOI
- 10.1016/S0896-6273(02)00604-9 · DOI · Paper page
- 10.3233/JAD-2010-1219 · DOI · Paper page
- 10.1016/j.mrfmmm.2009.08.016 · DOI
- 10.1093/hmg/ddl211 · DOI · Paper page
- 10.1111/j.1460-9568.2004.03188.x · DOI · Paper page
- 10.2174/156720506779025305 · DOI · Paper page
- 1990, Progress in Clinical and Biological Research, 360, 263
- 10.1016/S0378-1119(03)00769-8 · DOI · Paper page
- 10.1016/j.neuron.2006.05.022 · DOI · Paper page
- 10.1016/j.neurobiolaging.2003.10.010 · DOI
- 10.3727/096368910X528085 · DOI · Paper page
- 10.1016/j.brainres.2009.08.052 · DOI
- 10.1002/ana.20250 · DOI · Paper page
- 10.1016/j.biopsych.2009.08.018 · DOI
- 10.1016/S0168-0102(03)00005-1 · DOI
- 10.1016/j.expneurol.2004.11.017 · DOI
- 10.1016/S0166-4328(02)00082-7 · DOI
- 10.1006/exnr.1999.7289 · DOI · Paper page
- 10.1126/scitranslmed.3000258 · DOI · Paper page
- 10.1016/S0166-4328(02)00275-9 · DOI
- 10.1523/JNEUROSCI.1547-09.2009 · DOI · Paper page
- 10.1093/hmg/ddm022 · DOI · Paper page
- 10.1016/S0166-2236(02)02037-4 · DOI · Paper page
- 10.1016/j.clinph.2006.07.134 · DOI
- 10.1038/nn1860 · DOI · Paper page
- 10.1016/S0166-4328(97)00116-2 · DOI
- 10.1016/S0926-6410(00)00074-4 · DOI
- 10.1016/j.nbd.2011.04.011 · DOI · Paper page
- 10.1016/j.nlm.2007.05.007 · DOI
- 10.1159/000330861 · DOI · Paper page
- 10.1038/sj.npp.1301535 · DOI · Paper page
- 10.1016/j.bbr.2010.03.036 · DOI · Paper page
- 10.3233/JAD-2010-100240 · DOI · Paper page
- 10.1046/j.1365-2788.2000.00305.x · DOI · Paper page
- 10.2174/156720508784533286 · DOI · Paper page
- 2002, Journal of Neuroscience, 22, 2434, 10.1523/JNEUROSCI.22-07-02434.2002 · DOI · Paper page
- 10.1073/pnas.0909586107 · DOI · Paper page
- 10.1016/j.neuint.2010.02.001 · DOI
- 10.1124/mol.104.007864 · DOI
- 10.1016/S0306-4522(97)00546-0 · DOI
- 10.1016/S0079-6123(07)63018-0 · DOI
- 10.1016/j.neurobiolaging.2006.06.003 · DOI · Paper page
- 10.1002/cne.20744 · DOI · Paper page
- 10.1002/ana.410320510 · DOI · Paper page
- 1983, Clinical Neuropathology, 2, 1
- 10.1001/archneur.60.3.337 · DOI · Paper page
- 10.5414/NPP30104 · DOI
- 10.1002/mds.22307 · DOI · Paper page
- 10.1097/JGP.0b013e3181aad585 · DOI
- 10.1345/aph.1P341 · DOI · Paper page
- 10.1016/j.neurobiolaging.2004.05.010 · DOI · Paper page
- 1997, Acta Neurologica Scandinavica, 96, 236
- 10.1016/j.bcp.2005.05.019 · DOI
- 10.1016/S0169-328X(03)00092-5 · DOI
- 10.2174/187152707783399193 · DOI · Paper page
- 1986, Neurobiology of Aging, 7, 297, 10.1016/0197-4580(86)90010-2 · DOI
- 1989, Progress in Clinical and Biological Research, 317, 353
- 10.1016/S0197-0186(02)00049-9 · DOI · Paper page
- 10.1111/j.1601-183X.2007.00378.x · DOI · Paper page
- 2004, Progress in Brain Research, 146, 3
- 2005, Journal of Neuropathology and Experimental Neurology, 64, 263, 10.1093/jnen/64.4.263 · DOI · Paper page
- 10.1016/j.pneurobio.2006.09.001 · DOI
- 1995, NeuroReport, 6, 1063, 10.1097/00001756-199505090-00028 · DOI · Paper page
- 10.1016/j.neulet.2006.11.040 · DOI
- 10.1073/pnas.0908953107 · DOI · Paper page
- 10.1016/j.biopsych.2010.05.030 · DOI · Paper page
- 2002, Journal of Neural Transmission, 241
- 2012, Hippocampus, 22, 335
- 10.1186/1742-4933-7-2 · DOI
- 10.3389/fnagi.2010.00036 · DOI · Paper page
- 10.1016/j.neuroscience.2010.02.050 · DOI · Paper page
- 10.1016/j.bbr.2010.12.030 · DOI · Paper page
- 2005, Cell Transplantation, 14, 21, 10.3727/000000005783983313 · DOI
- 10.1111/j.1471-4159.2010.06622.x · DOI · Paper page
- 10.1016/j.pnpbp.2008.10.006 · DOI
- 10.1002/ar.20969 · DOI
- 10.1016/j.jns.2010.08.029 · DOI
- 2000, Journal of Neuropathology and Experimental Neurology, 59, 1011, 10.1093/jnen/59.11.1011 · DOI · Paper page
- 10.1016/S0891-5849(02)00861-4 · DOI
- 2001, Journal of Neural Transmission, 223
- 10.1196/annals.1427.010 · DOI · Paper page
- 10.1136/bmj.39465.544028.AE · DOI · Paper page
- 10.1016/j.expneurol.2008.11.021 · DOI · Paper page
- 10.1038/35037739 · DOI · Paper page
- 10.1093/hmg/ddm049 · DOI
Cited by
Ageing, Cellular Senescence and Neurodegenerative Disease
Kritsilis, M., V. Rizou, S., Koutsoudaki, P. N., Evangelou, K., Gorgoulis, V. G., & Papadopoulos, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102937 · Cited by 448
Dementia in Down syndrome: unique insights for Alzheimer disease research
Lott, I. T., & Head, E. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0132-6 · Cited by 383
Functional neuroanatomy of the central noradrenergic system
Szabadi, E. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113490326 · Cited by 335
Down syndrome and Alzheimer's disease: common pathways, common goals
Hartley, D., Blumenthal, T., Carrillo, M., DiPaolo, G., Esralew, L., Gardiner, K., Granholm, A.-C., Iqbal, K., Krams, M., Lemere, C., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.10.007 · Cited by 290
“[24] Lockrow JP, Fortress AM, Granholm AC.”
BackgroundSelf-citationChen, C., Jiang, P., Xue, H., Peterson, S. E., Tran, H. T., McCann, A. E., Parast, M. M., Li, S., Pleasure, D. E., Laurent, L. C., et al. (2014) · Nature Communications · doi:10.1038/ncomms5430 · Cited by 219
Metadata
- Authors
- Lockrow, J. P., Fortress, A. M., & Granholm, A.-C. E.
- Venue
- Current Gerontology and Geriatrics Research
- Publisher
- Hindawi Limited
- Published
- 2012
- Volume
- 2012
- Pages
- 1-13
- ISSN
- 1687-7063 (ISSN-L)
- 1687-7071
- OpenAlex
- W2020657007
- Cited by
- 63
- References
- 28
- FWCI
- 5.21
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.